

## 09 | MedImmune

1 Medimmune Way, Gaithersburg, MD 20878  
Tel: (877) 633-4411 Fax: (301) 398-9000  
[www.medimmune.com](http://www.medimmune.com)

|                           |              |
|---------------------------|--------------|
| <b>HEADCOUNT</b>          | 2,215        |
| <b>YEAR ESTABLISHED</b>   | 1988         |
| <b>BIOPHARMA REVENUES</b> | \$1,221 flat |
| <b>TOTAL REVENUES</b>     | \$1,277 +3%  |
| <b>ROYALTY REVENUES</b>   | \$56 +143%   |
| <b>NET INCOME</b>         | \$49 n/a     |
| <b>R&amp;D BUDGET</b>     | \$449 +17%   |

### DRUGS APPROVED/LAUNCHED

| Drug    | Indication              |
|---------|-------------------------|
| flumist | influenza (formulation) |

### DRUGS IN PHASE IIB AND BEYOND

| Drug                 | Indication                               |
|----------------------|--|
| caiv-t               | cold-adapted trivalent influenza vaccine |
| numax                | lower respiratory tract disease from RSV |
| epstein-barr vaccine | epstein-barr virus                       |

### EARLY RESEARCH PROJECTS

| Drug                 | Indication                                   |
|----------------------|--|
| medi-534             | RSV and PIV-3 viruses                        |
| vaccine programs     | (hMPV) and parainfluenzavirus type 3 (PIV-3) |
| pneumococcal vaccine | <i>streptococcus pneumoniae</i>              |
| h5n1 vaccine         | h5n1 influenza                               |
| medi-543             | cancer                                       |

|                            |  |
|----------------------------|--|
| medi-542                   | cancer   |
| medi-546                   | lupus/SLE  |
| hedgehog pathway inhibitor | cancer   |
| hmgb-1                     | chronic inflammatory diseases                                  |
| ipi-504                    | gastrointestinal stromal tumors and other soft tissue sarcomas |
| mt103                      | B-cell-derived non-Hodgkin's lymphoma                          |

### TOP SELLING DRUGS

| Drug    | Indication                       | \$      | (+/- %) |
|---------|----------------------------------|---------|---------|
| synagis | respiratory syncytial virus      | \$1,098 | -1%     |
| ethyol  | renal toxicity from chemotherapy | \$87    | -8%     |
| fluMist | influenza                        | \$36    | 71%     |

Account for 100% of total biopharma sales, same in 2005.

## 10 | Millennium

40 Landsdowne St., Cambridge, MA 02139  
Tel: (800) 390-5663 Fax: (617) 374-7788  
[www.mlnm.com](http://www.mlnm.com)

|                           |             |
|---------------------------|-------------|
| <b>HEADCOUNT</b>          | 947         |
| <b>YEAR ESTABLISHED</b>   | 1993        |
| <b>BIOPHARMA REVENUES</b> | \$220 -30%  |
| <b>TOTAL REVENUES</b>     | \$487 -13%  |
| <b>ROYALTY REVENUES</b>   | \$130 +253% |
| <b>NET LOSS</b>           | -\$44 n/a   |
| <b>R&amp;D BUDGET</b>     | \$318 -7%   |

### DRUGS PENDING APPROVAL

| Drug    | Indication                                  |
|---------|---|
| velcade | relapsed or refractory mantle cell lymphoma |

### DRUGS IN PHASE IIB AND BEYOND

| Drug    | Indication                        |
|---------|-----------------------------------|
| velcade | follicular/marg.zn, NSCLC, tumors |
| mln0518 | acute myelogenous leukemia        |
| mln120  | atherosclerosis                   |
| mln1202 | multiple sclerosis                |
| mln3897 | rheumatoid arthritis              |

### EARLY RESEARCH PROJECTS

| Drug    | Indication                |
|---------|---------------------------|
| mln8054 | advanced malignancies     |
| mln6095 | asthma, allergic rhinitis |

|         |                        |
|---------|------------------------|
| mln0415 | inflammatory disorders |
| mln3701 | rheumatoid arthritis   |
| mln4924 | advanced cancer        |

### TOP SELLING DRUGS

| Drug    | Indication       | \$    | (+/- %) |
|---------|------------------|-------|---------|
| velcade | multiple myeloma | \$221 | 15%     |

Account for 100% of total biopharma sales, same as in 2005.

### KEY PERSONNEL

Deborah Dunsire, M.D.  
*president and chief executive officer*  
Christophe Bianchi, M.D.  
*executive vice president, commercial operations*  
Joseph B. Bolen, Ph.D.  
*chief scientific officer*